Theravance Hits New 52-Week Low at $22.01 (THRX)
Shares of Theravance (NASDAQ:THRX) hit a new 52-week low on Monday , Analyst Ratings Network.com reports. The stock traded as low as $22.01 and last traded at $22.11, with a volume of 896,120 shares changing hands. The stock had previously closed at $22.94.
A number of analysts have recently weighed in on THRX shares. Analysts at Morgan Stanley downgraded shares of Theravance from a “buy” rating to a “neutral” rating in a research note on Thursday. They now have a $31.00 price target on the stock, down previously from $34.00. Separately, analysts at Bank of America downgraded shares of Theravance from a “buy” rating to a “neutral” rating in a research note on Thursday. They now have a $31.00 price target on the stock, down previously from $34.00. Finally, analysts at Stifel Nicolaus downgraded shares of Theravance to an “underweight” rating in a research note on Monday, July 21st. They now have a $7.00 price target on the stock, down previously from $12.00. One investment analyst has rated the stock with a sell rating and six have issued a hold rating to the company. The stock currently has an average rating of “Hold” and an average price target of $23.60.
The stock has a 50-day moving average of $28.01 and a 200-day moving average of $26.71. The company’s market cap is $2.478 billion.
Theravance (NASDAQ:THRX) last released its earnings data on Tuesday, May 6th. The company reported ($0.62) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.53) by $0.09. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $4.52 million. During the same quarter last year, the company posted ($0.39) earnings per share. Theravance’s revenue was down 87.3% compared to the same quarter last year. Analysts expect that Theravance will post $-1.19 EPS for the current fiscal year.
Theravance, Inc (NASDAQ:THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.